Company Filing History:
Years Active: 2017-2020
Title: Nadja Hilger: Innovator in Immunology
Introduction
Nadja Hilger is a prominent inventor based in Leipzig, Germany. She has made significant contributions to the field of immunology, particularly in the development of anti-CD4 antibodies. With a total of three patents to her name, her work focuses on preventing graft-versus-host disease (GVHD), a serious complication that can occur after stem cell transplants.
Latest Patents
One of her latest patents involves an innovative in vitro method for modifying a cell graft containing immune cells. This method includes incubating the cell graft with an anti-CD4 antibody for a duration ranging from 1 minute to 7 days, followed by the removal of unbound antibodies from the graft. The invention also addresses the modification of antibodies that react to the CD4 human leukocyte antigen, aiming to create anti-CD4 antibodies with fewer potential T-cell epitopes while maintaining their ability to bind to CD4. This ensures that the specificity and mode of action of the anti-CD4 antibodies remain unaffected by the modifications.
Career Highlights
Nadja has worked with the Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., a leading research organization in Germany. Her experience in this esteemed institution has allowed her to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Throughout her career, Nadja has collaborated with notable colleagues such as Stephan Fricke and Frank Emmrich. These partnerships have further enhanced her research and innovation in immunology.
Conclusion
Nadja Hilger is a trailblazer in the field of immunology, with her innovative patents and collaborations paving the way for advancements in preventing graft-versus-host disease. Her contributions are vital to improving patient outcomes in stem cell transplantation.